Published in Adv Protein Chem on January 01, 2001
Lovastatin: Immunomodulatory Value Evaluation (LIVE) | NCT00721305
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
Isoprenoids as mediators of the biological effects of statins. J Clin Invest (2002) 2.19
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13
Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res (2008) 1.64
Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. Trials (2009) 0.82
Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis. PLoS One (2016) 0.80
Atherosclerosis: A Link Between Lipid Intake and Protein Tyrosine Nitration. Lipid Insights (2008) 0.79
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med (1993) 4.61
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation (1998) 2.40
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf (1996) 1.85
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med (1996) 1.68
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol (1999) 1.62
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest (1982) 1.54
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol (1998) 1.32
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation (1987) 1.13
Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol (1999) 1.10
A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther (1994) 1.04
Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis (1982) 1.00
Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med (1987) 0.92
The cholesterol controversy. BMJ (1992) 0.92
A study of the possible role of prostaglandins in decidualization using a nonsurgical method for the instillation of fluids into the rat uterine lumen. J Reprod Fertil (1976) 0.89
Dynamics and kinetics of ophthalmic timolol. Clin Pharmacol Ther (1980) 0.86
The effect in man of (+)-propranolol and racemic propranolol on renin secretion stimulated by orthostatic stress. Clin Sci (1973) 0.86
Calcium channel blocker-simvastatin interaction. Clin Pharmacol Ther (1999) 0.81
The clinical efficacy and safety of lovastatin and MK-733--an overview. Eur Heart J (1987) 0.81
HMG-CoA reductase inhibitors and sleep. Clin Pharmacol Ther (1992) 0.79
HMG-CoA reductase inhibitors, gemfibrozil, and myopathy. Am J Cardiol (1995) 0.78
Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states. Clin Pharmacol Ther (1981) 0.78
Lipid-lowering therapy for patients with or at risk of coronary artery disease. Curr Opin Cardiol (1996) 0.78
Lovastatin-associated sleep and mood disturbances. Am J Med (1995) 0.78
Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio. Clin Pharmacol Ther (1981) 0.75
Changes in estrogen receptor levels during deciduomata development in the pseudopregnant rat. Endocrinology (1977) 0.75
Relative safety and efficacy of pravastatin. Clin Pharm (1993) 0.75
Blood cholesterol measurement in young adults. JAMA (1993) 0.75
Statin therapy and CHD. Lancet (1996) 0.75
Carcinogenicity of lipid-lowering drugs. JAMA (1996) 0.75
Lipid lowering drugs. BMJ (1990) 0.75
Lovastatin and myopathy. Am J Med (1994) 0.75
L-643.441: an H2-receptor antagonist with potent and long-lasting effects in man. Br J Clin Pharmacol (1985) 0.75
Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol (1992) 0.75
Lovastatin: follow-up ophthalmologic data. JAMA (1988) 0.75
Effect of copper and platinum intrauterine devices on endometrial morphology and implantation in the rabbit. J Reprod Fertil (1977) 0.75
Changes in progesterone receptor levels during deciduomata development in the pseudopregnant rat. Endocrinology (1977) 0.75
AHA Conference Report on Cholesterol. Drug therapy. Circulation (1989) 0.75
Indacrinone: modification of diuretic, uricosuric, and kaliuretic actions by amiloride. Clin Pharmacol Ther (1980) 0.75
Induction of deciduomata by intrauterine copper in the rabbit. J Reprod Fertil (1975) 0.75
The effect of hormonal state on the dissolution of copper in the rabbit uterus. Contraception (1974) 0.75
Enantiomers of indacrinone: a new approach to producing an isouricemic diuretic. Clin Exp Hypertens A (1982) 0.75